Autoimmunity and geriatrics: Clinical significance of autoimmune manifestations in the elderly

Lupus

Volumn 12, Issue 5, 2003, Pages 341-355

  Ramos Casals, M ^a,c   Garcia Carrasco M ^a   Brito, M P ^a   Lopez Soto A ^b   Font, J ^a  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

Author keywords

Ageing; Autoantibodies; Autoimmune diseases; Autoimmunity; Geriatrics; Immunosenescence

Indexed keywords

ANTINUCLEAR ANTIBODY; AUTOANTIBODY; MITOCHONDRION ANTIBODY; PARIETAL CELL ANTIBODY; PHOSPHOLIPID ANTIBODY; RHEUMATOID FACTOR; SMOOTH MUSCLE ANTIBODY;

AGING; ANTIBODY PRODUCTION; ANTIPHOSPHOLIPID SYNDROME; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CELLULAR IMMUNITY; DERMATOMYOSITIS; GIANT CELL ARTERITIS; HUMAN; HUMORAL IMMUNITY; IMMUNOREGULATION; POLYARTERITIS NODOSA; POLYMYOSITIS; PRIORITY JOURNAL; REVIEW; RHEUMATIC POLYMYALGIA; RHEUMATOID ARTHRITIS; SENESCENCE; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; WEGENER GRANULOMATOSIS;

AGED; AGING; AUTOANTIBODIES; AUTOIMMUNE DISEASES; AUTOIMMUNITY; GERIATRIC ASSESSMENT; HUMANS; IMMUNE SYSTEM; PREVALENCE;

EID: 0038579780     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/0961203303lu383ed     Document Type: Review

References (190)

1. Ginaldi L, De Martinis M, D'Ostilio A et al. Cell proliferation and apoptosis in the immune system in the elderly. Immunol Res 2000; 21: 31-38.
2. Ginaldi L, De Martinis M, D'Ostilio A, Marini L, Loreto MF, Quaglino D. Immunological changes in the elderly. Aging (Milano) 1999; 11: 281-286.
3. Goidl EA, Michelis MA, Siskind GW, Weksler ME. Effect of age on the induction of autoantibodies. Clin Exp Immunol 1981; 44: 24-30.
4. Miller RA. Age-related changes in T cell surface markers: a longitudinal analysis in genetically heterogeneous mice. Mech Ageing Dev 1997; 96: 181-196.
5. Burton GF, Kosco MH, Szakal AK, Tew JG. Nucleosomes and the secondary antibody response. Immunology 1991; 73: 271-276.
6. Gabriel H, Schmitt B, Kindermann W. Age-related increase of CD45RO+ lymphocytes in physically active adults. Eur J Immunol 1993; 23: 2704-2706.
7. Mazari L, Lesourd BM. Nutritional influences on immune response in healthy aged persons. Mech Ageing Dev 1998; 104: 25-40.
8. Ershler WB, Sun WH, Binkley N et al. Interleukin-6 and aging: blood levels and mononuclear cell production increase with advancing age and in vitro production is modifiable by dietary restriction. Lymphokine Cytokine Res 1993; 12: 225-230.
9. Miller RA. Gerontology as oncology. Research on aging as the key to the understanding of cancer. Cancer 1991; 68: 2496-2501.
10. Antonaci S, Jirillo E, Bonomo L. Immunoregulation in aging. Diagn Clin Immunol 1987; 5: 55-61.
11. Kendall MD, Johnson HR, Singh J. The weight of the human thymus gland at necropsy. J Anat 1980; 131: 483-497.
12. Subbarao B, Morris J, Kryscio RJ. Phenotypic and functional properties of B lymphocytes from aged mice. Mech Ageing Dev 1990; 51: 223-241.
13. Utsuyama M, Hirokawa K, Kurashima C et al. Differential age-change in the numbers of CD4 + CD45RA+ and CD4+CD29+ T cell subsets in human peripheral blood. Mech Ageing Dev 1992; 63: 57-68.
14. Kishimoto S, Tomino S, Inomata K et al. Age-related changes in the subsets and functions of human T lymphocytes. J Immunol 1978; 121: 1773-1780.
15. Pahwa SG, Pahwa RN, Good RA. Decreased in vitro humoral immune responses in aged humans. J Clin Invest 1981; 67: 1094-1102.
16. Antonaci S, Polignano A, Tortorella C, Garofalo AR, Jirillo E, Bonomo L. Role of interleukin 2, interleukin 4 and interleukin 5 in the T helper cell-driven B cell polyclonal differentiation in the elderly. Cytobios 1992; 70: 77-85.
17. Francus T, Chen YW, Staiano-Coico L, Hefton JM. Effect of age on the capacity of the bone marrow and the spleen cells to generate B lymphocytes. J Immunol 1986; 137: 2411-2417.
18. Buckley CE III, Dorsey FC. The effect of aging on human serum immunoglobulin concentrations. J Immunol 1970; 105: 964-972.
19. Rink L, Seyfarth M. Characteristics of immunologic test values in the elderly. Z Gerontol Geriatr 1997; 30: 220-225.
20. Pandey PJ, Fudenberg HH, Ainsworth SK, Loadholt BC. Autoantibodies in healthy subjects of different age groups. Mech Aging Dev 1979; 10: 399-404.
21. Gordon J, Rosenthal M. Failure to detect age-related increase of nonpathological autoantibodies. Lancet 1984; 1: 231.
22. Tomer Y, Shoenfeld Y. Ageing and autoantibodies. Autoimmunity 1988; 1: 141-149.
23. Talor E, Rose NR. Hypothesis: the aging paradox and autoimmune disease. Autoimmunity 1991; 8: 245-249.
24. Rose NR. Thymus function, ageing and autoimmunity. Immunol Lett 1994; 40: 225-230.
25. Hallgren HM, Buckley CE III, Gilbertsen VA, Yunis EJ. Lymphocyte phytohemagglutinin responsiveness, immunoglobulins and autoantibodies in aging humans. J Immunol 1973; 111: 1101-1107.
26. Andersen P. Correlation of smooth-muscle and nuclear antibodies in normal subjects. Clin Exp Immunol 1977; 27: 74-77.
27. Delespesse G, Gausset P, Sarfati M, Dubi-Rucquoy M, Debisschop MJ, van Haelst L. Circulating immune complexes in old people and in diabetics: correlation with autoantibodies. Clin Exp Immunol 1980; 40: 96-102.
28. Goodwin JS, Searles RP, Tung KS. Immunological responses of healthy elderly population. Clin Exp Immunol 1982; 48: 403-410.
29. Ockhuizen TH, Pandey JP, Galbraith GMP, Fudenberg HH, Hames CG. Autoantibodies and immunoglobulin allotypes in healthy north American blacks of different age groups. Mech Aging Dev 1982; 19: 103-111.
30. Manoussakis MN, Tzioufas AG, Silis MP, Pange PJ, Goudevenos J, Moutsopoulos HM. High prevalence of anti-cardiolipin and other autoantibodies in a healthy elderly population. Clin Exp Immunol 1987; 69: 557-565.
31. Moulias R, Proust J, Wang A et al. Age-related increase in autoantibodies. Lancet 1984; 1: 1128-1129.
32. Hijmans W, Radl J, Bottazzo GF, Doniach D. Autoantibodies in highly aged humans. Mech Ageing Dev 1984; 26: 83-89.
33. Fields RA, Toubbeh H, Searles RP, Bankhurst AD. The prevalence of anticardiolipin antibodies in a healthy elderly population and its association with antinuclear antibodies. J Rheumatol 1989; 16: 623-625.
34. Ruffatti A, Rossi L, Calligaro A et al. Autoantibodies of systemic rheumatic diseases in the healthy elderly. Gerontology 1990; 36: 104-111.
35. Manoussakis MN, Stavropoulos ED, Germanidis GS et al. Soluble interleukin-2 receptors and autoantibodies in the serum of healthy elderly individuals. Autoimmunity 1990; 7: 129-137.
36. Chakravarty KK, Gray RE, Webley M, Byron MA, Wozniak J. Prevalence of anticardiolipin antibodies in the elderly British population. Postgrad Med J 1991; 67: 358-361.
37. Perez L, Rodriguez C, Sepulveda JA, Silva MC. Autoimmune phenomena in the elderly. Rev Med Chil 1991; 119: 287-292.
38. Olujide-Oyeyinka G, Samusa-Salimonu L, OlufunmilayoOgunsile M. The role of circulating immune complexes; antinuclear and rheumatoid factor autoantibodies in aging in Nigerians. Mech Aging Dev 1995; 85: 73-81.
39. Xavier RM, Yamauchi Y, Nakamura M, Tanigawa Y, Ishikura H, Tsunematsu T, Kobayashi S. Antinuclear antibodies in healthy aging people: a prospective study. Mech Ageing Dev 1995; 78: 145-154.
40. Azizah MR, Shahnaz M, Zulkifli MN, Nasuruddin BA. Anti-nuclear, anti mitochondrial, anti-smooth muscle and anti-parietal cell antibodies in the healthy Malaysian population. Malays J Pathol 1995; 17: 83-86.
41. Teo SK, Soon PC, Ng SC. Auto-antibodies in the hospitalised Oriental elderly. Singapore Med J 1995; 36: 609-611.
42. Slater CA, Davis RB, Shemerling RH. Antinuclear antibody testing: a study of clinical utility. Arch Intern Med 1996; 156: 1421-1425.
43. Maillefert JF, Pfitzenmeyer P, Thenet M et al. Prevalence of ANCA in a hospitalized elderly French population. Clin Exp Rheumatol 1997; 15: 603-607.
44. Candore G, Di Lorenzo G, Mansueto P et al. Prevalence of organspecific and non organ-specific autoantibodies in healthy centenarians. Mech Ageing Dev 1997; 94: 183-190.
45. Velluzzi F, Caradonna A, Boy MF et al. Thyroid and celiac disease: clinical, serological, and echographic study. Am J Gastroenterol 1998; 93: 976-979.
46. Andersen-Ranberg K, Jeune B, Hoier-Madsen M, Hegedus L. Thyroid function, morphology and prevalence of thyroid disease in a population-based study of Danish centenarians. J Am Geriatr Soc 1999; 47: 1238-1243.
47. Richaud-Patin Y, Cabiedes J, Jakez-Ocampo J, Vidaller A, Llorente L. High prevalence of protein-dependent and protein-independent antiphospholipid and other autoantibodies in healthy elders. Thromb Res 2000; 99: 129-133.
48. Njemini R, Meyers I, Demanet C, Smitz J, Sosso M, Mets T. The prevalence of autoantibodies in an elderly sub-Saharan African population. Clin Exp Immunol 2002; 127: 99-110.
49. Newkirk MM. Rheumatoid factors: host resistance or autoimmunity? Clin Immunol 2002; 104: 1-13.
50. Yung L, in Loeser RF Jr, O'Rourke KS (eds), Rheumatic disease clinics of North America (Spanish edition). Panamericana: Madrid, pp 475-494.
51. Silvestris F, Anderson W, Goodwin JS, Williams RC Jr. Discrepancy in the expression of autoantibodies in healthy aged individuals. Clin Immunol Immunopathol 1985; 35: 234-244.
52. Wilkens RF, Whitaker RR, Anderson RV et al. Significance of antinuclear factors in older persons. Ann Rheum Dis 1967; 26: 306-309.
53. Iakoubov LZ, Torchilin VP. A novel class of antitumour antibodies: nucleosome-restricted antinuclear autoantibodies (ANA) from healthy aged nonautoimmune mice. Oncol Res 1997; 9: 439-446.
54. Naschitz JE, Rosner I, Rozenbaum M et al. Cancer-associated rheumatic disorders: clues to occult neoplasia. Semin Arthritis Rheum 1995; 24: 231-241.
55. Torchilin VP, Iakoubov LZ, Estrov Z. Antinuclear autoantibodies as potential antineoplastic agents. Trends Immunol 2001; 22: 424-427.
56. Bell DA, Morrison B. The spontaneous apoptotic cell death of normal human lymphocytes in vitro: the release of, and immunoproliferative response to, nucleosomes in vitro. Clin Immunol Immunopathol 1991; 60: 13-26.
57. LeLann AD, Foumie GJ, Boissier I et al. In vitro inhibition of natural-killer-mediated lysis by chromatin fragments. Cancer Immunol Immunother 1994; 39: 185-192.
58. Wyllie AH. Apoptosis (the 1992 Frank Rose Memorial Lecture). Br J Cancer 1993; 67: 205-208.
59. Raz E, Ben-Bassat H, Davidi T, Shlomai Z, Eilat D. Cross-reactions of anti-DNA autoantibodies with cell surface proteins. Eur J Immunol 1993; 23: 383-390.
60. Palo J, Duchesne J, Wikstrom J. Malignant diseases among patients with multiple sclerosis. J Neurol 1977; 216: 217-222.
61. Blaes F, Klotz M, Huwer H et al. Antineural and antinuclear autoantibodies are of prognostic relevance in non-small cell lung cancer. Ann Thorac Surg 2000; 69: 254-258.
62. Syrigos KN, Charalambopoulos A, Pliarchopoulou K, Varsamidakis N, Machairas A, Mandrekas D. The prognostic significance of autoantibodies against dsDNA in patients with colorectal adenocarcinoma. Anticancer Res 2000; 20: 4351-4353.
63. Kuroi K, Tanaka C, Toi M. Plasma nucleosome levels in node-negative breast cancer patients. Breast Cancer 1999; 6: 361-364.
64. Juby A, Davis P, Genge T, McElhaney J. Anticardiolipin antibodies in two elderly subpopulations. Lupus 1995; 4: 482-485.
65. Mosek A, Yust I, Treves TA, Vardinon N, Korczyn AD, Chapman J. Dementia and antiphospholipid antibodies. Dement Geriatr Cogn Disord 2000; 11: 36-38.
66. Tanne D, D'Olhaberriague L, Trivedi AM, Salowich-Palm L, Schultz LR, Levine SR. Anticardiolipin antibodies and mortality in patients with ischemic stroke: a prospective follow-up study. Neuroepidemiology 2002; 21: 93-99.
67. Godfrey T and D'Cruz D. Antiphospholipid Syndrome: General Features in Hughes Syndrome (Antiphospholipid Syndrome). Khamashta: London, pp 8-19.
68. Moscardi F, Ianiro JL, Maxit MJ. Antineurotrophil cytoplasmic antibodies (ANCA) in the elderly. Medicina (Bueras Aires) 1997; 57: 36-40.
69. Reinhold-Keller E, Zeidler A, Gutfleisch J, Peter HH, Raspe HH, Gross WL. Giant cell arteritis is more prevalent in urban than in rural populations: results of an epidemiological study of primary systemic vasculitides in Germany. Rheumatology (Oxford) 2000; 39: 1396-1402.
70. Salvarani C, Macchioni PL, Tartoni PL et al. Polymyalgia rheumatica and giant cell arteritis: a 5-year epidemiologic and clinical study in Reggio Emilia, Italy. Clin Exp Rheumatol 1987; 5: 205-215.
71. Calamia KT, Hunder GG. Clinical manifestations of giant cell (temporal) arteritis. Clin Rheum Dis 1980; 6: 389-403.
72. Calamia KT, Hunder GG. Giant cell arteritis (temporal arteritis) presenting as fever of undetermined origin. Arthritis Rheum 1981; 24: 141.
73. Knockaert DC, Vanneste LJ, Bobbaers HJ. Fever of unknown origin in elderly patients. J Am Geriatr Soc 1993; 41: 1187-1192.
74. Huston KA, Hunder GG, Lie JT, Kennedy RH, Elveback LR. Temporal arteritis: a 25-year epidemiologic, clinical, and pathologic study. Ann Intern Med. 1978; 88: 162-167.
75. Salvarani C, Cantini F, Boiardi L, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. New Engl J Med 2002; 347: 261-271.
76. Gonzalez-Gay MA, Alonso MD, Aguero JJ, Bal M, FernandezCamblor B, Sanchez-Andrade A. Temporal arteritis in a northwestern area of Spain: study of 57 biopsy proven patients. J Rheumatol 1992; 19: 277-280.
77. Hunder GG, Bloch DA, Michel BA et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 1990; 33: 1122-1128.
78. Cantini F, Salvarani C, Olivieri I et al. Erythrocyte sedimentation rate and C-reactive protein in the evaluation of disease activity and severity in polymyalgia rheumatica: a prospective follow-up study. Semin Arthritis Rheum 2000; 30: 17-24.
79. Salvarani C, Hunder GG. Giant cell arteritis with low erythrocyte sedimentation rate: frequency of occurrence in a population-based study. Arthritis Rheum 2001; 45: 140-145.
80. Liozon E, Herrmann F, Ly K, Robert PY, Loustaud V, Soria P, Vidal E. Risk factors for visual loss in giant cell (temporal) arteritis: a prospective study of 174 patients. Am J Med 2001; 111: 211-217.
81. Hayreh SS, Podhajsky PA, Raman R, Zimmerman B. Giant cell arteritis: validity and reliability of various diagnostic criteria. Am J Ophthalmol 1997; 123: 285-296.
82. Weyand CM, Kaiser M, Yang H, Younge B, Goronzy JJ. Therapeutic effects of acetylsalicylic acid in giant cell arteritis. Arthritis Rheum 2002; 46: 457-466.
83. Ray-Chaudhuri N, Kine DA, Tijani SO et al. Effect of prior steroid treatment on temporal artery biopsy findings in giant cell arteritis. Br J Ophthalmol 2002; 86: 530-532.
84. Schmidt WA, Gromnica-Ihle E. Incidence of temporal arteritis in patients with polymyalgia rheumatica: a prospective study using colour Doppler ultrasonography of the temporal arteries. Rheumatology (Oxford) 2002; 41: 46-52.
85. Chutka DS, Evans JM, Fleming KC, Mikkelson KG. Symposium on geriatrics - Part I: Drug prescribing for elderly patients. Mayo Clin Proc 1995; 70: 685-693.
86. Chevalet P, Barrier JH, Glemarec J et al. Horton's disease in elderly patients aged over 75: clinical course, complications of corticotherapy. Comparative study of 164 patients. Towards a reduced initial dose. Rev Med Interne 2001; 22: 624-630.
87. Nesher G, Sonnenblick M, Friedlander Y. Analysis of steroid related complications and mortality in temporal arteritis: a 15-year survey of 43 patients. J Rheumatol 1994; 21: 1283-1286.
88. Jover JA, Hemandez-Garcia C, Morado IC, Vargas E, Banares A, Femandez-Gutierrez B. Combined treatment of giant-cell arteritis with methotrexate and prednisone. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001; 134: 106-114.
89. Hoffman GS, Cid MC, Hellmann DB et al. A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum 2002; 46: 1309-1318.
90. Cohen MD, Ginsburg WW. Polymyalgia rheumatica. Rheum Dis Clin N Am 1990; 16: 325-339.
91. Salvarani C, Gabriel SE, O'Fallon WM, Hunder GG. Epidemiology of polymyalgia rheumatica in Olmsted County, Minnesota, 1970-1991. Arthritis Rheum 1995; 38: 369-373.
92. Salvarani C, Gabriel SE, O'Fallon WM, Hunder GG. The incidence of giant cell arteritis in Olmsted County, Minnesota: apparent fluctuations in a cyclic pattern. Ann Intern Med 1995; 123: 192-194.
93. Noltorp S, Svensson B. High incidence of polymyalgia rheumatica and giant cell arteritis in a Swedish community. Clin Exp Rheumatol 1991; 9: 351-355.
94. Elling P, Olsson AT, Elling H. Synchronous variations of the incidence of temporal arteritis and polymyalgia rheumatica in different regions of Denmark; association with epidemics of Mycoplasma pneumoniae infection. J Rheumatol 1996; 23: 112-119.
95. Salvarani C, Macchioni P, Zizzi F et al. Epidemiologic and immunogenetic aspects of polymyalgia rheumatica and giant cell arteritis in northern Italy. Arthritis Rheum 1991; 34: 351-356.
96. Doran MF, Crowson CS, O'Fallon WM, Hunder GG, Gabriel SE. Trends in the incidence of polymyalgia rheumatica over a 30 year period in Olmsted County, Minnesota, USA. J Rheumatol 2002; 29: 1694-1697.
97. Gran JT, Myklebust G, Wilsgaard T, Jacobsen BK. Survival in polymyalgia rheumatica and temporal arteritis: a study of 398 cases and matched population controls. Rheumatology (Oxford) 2001; 40: 1238-1242.
98. Gabriel SE, O'Fallon WM, Achkar AA, Lie JT, Hunder GG. The use of clinical characteristics to predict the results of temporal artery biopsy among patients with suspected giant cell arteritis. J Rheumatol 1995; 22: 93-96.
99. Gabriel SE, Sunku J, Salvarani C, O'Fallon WM, Hunder GG. Adverse outcomes of antiinflammatory therapy among patients with polymyalgia rheumatica. Arthritis Rheum 1997; 40: 1873-1878.
100. Saag KG, Emkey R, Schnitzer TJ et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. New Engl J Med 1998; 339: 292-299.
101. Marie I, Hatron PY, Levesque H et al. Influence of age on characteristics of polymyositis and dermatomyositis in adults. Medicine (Baltimore) 1999; 78: 139-147.
102. Pautas E, Cherin P, Piette JC, Pelletier S, Wechsler B, Cabane J, Herson S. Features of polymyositis and dermatomyositis in the elderly: a case-control study. Clin Exp Rheumatol 2000; 18: 241-244.
103. Tavernier B, Richard D, Gaudet M. Iatrogenic pathology in the elderly. Results of a prospective study of 1164 patients on 12 months. Rev Med (France) 1983; 6: 239-243.
104. Saint-Jean O, Berigaud S, Bouchon JP. Polypathology and co-morbidity: a dynamic way for describing morbidity in aged patients. Study of 100 patients, aged 80 and over, in a short-stay geriatric internal medicine unit. Ann Med Interne (Paris) 1991; 142: 563-569.
105. Mullges W, Naumann M, Reichmann H. Is chronic dermato- or polymyositis misdiagnosed as 'weakness of old age'? Dtsch Med Wochenschr 1993; 118: 1520-1524.
106. Hochberg MC, Lopez-Acuna D, Gittelsohn AM. Mortality from polymyositis and dermatomyositis in the United States, 1968-1978. Arthritis Rheum 1983; 26: 1465-1471.
107. Callen JP. Relation between dermatomyositis and polymyositis and cancer. Lancet 2001; 357: 85-86.
108. Rachima Maoz C, Langevitz, Livneh A et al. High incidence of malignancies in patients with dermatomyositis and polymyositis: a 11 year analysis. Semin Arthirtis Rheum 1998; 27: 319-324.
109. Fudman EJ, Schnitzer TJ. Dermatomyosytis without creatine kinase elevation: poor prognostic sign. Am J Med 1986; 80: 329-332.
110. Klippel JH, Dieppe PA. Rheumatology, 2nd edn. Mosby: London, 1998.
111. Hill CL, Zhang Y, Sigurgeirsson B, Pukkala E, Mellemkjaer L, Airio A, Evans SR, Felson DT. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet 2001; 357: 96-100.
112. Ship JA, Pillemer SR, Baum BJ. Xerostomia and the geriatric patient. J Am Geront Soc 2002; 50: 535-543.
113. Astor FC; Hanft KL; Ciocon JO. Xerostomia: a prevalent condition in the elderly. Ear Nose Throat J 1999; 78: 476-479.
114. Baum BJ. Evaluation of stimulated parotid saliva flow rate in different age groups. J Dent Res 1981; 60: 1292-1296.
115. Heft MW, Baum BJ. Unstimulated and stimulated parotid salivary flow rate in individuals of different ages. J Dent Res 1984; 63: 1182-1185.
116. Challacombe SJ, Percival RS, Marsh PD. Age-related changes in immunoglobulin isotypes in whole and parotid saliva and serum in healthy individuals. Oral Microbiol Immunol 1995; 10: 202-207.
117. Ship JA, Nolan NE, Puckett SA. Longitudinal analysis of parotid and submandibular salivary flow rates in healthy, different-aged adults. J Gerontol A Biol Sci Med Sci 1995; 50: M285-M289.
118. Ship JA, Baum BJ. Is reduced salivary flow normal in old people? Lancet 1990; 336: 1507.
119. Mandel ID. Sialochemistry in diseases and clinical situations affecting salivary glands. Crit Rev Clin Lab Sci 1980; 12: 321-366.
120. Atkinson JC, Fox PC. Salivary gland dysfunction. Clin Geriatr Med 1992; 8: 499-511.
121. Wu AJ, Ship JA. A characterization of major salivary gland flow rates in the presence of medications and systemic diseases. Oral Surg Oral Med Oral Pathol 1993; 76: 301-306.
122. Atkinson JC, Wu A. Salivary gland dysfunctions: causes, symptoms, treatment. J Am Dent Assoc 1994; 125: 409-416.
123. Sreebny LM, Schwartz SS. A reference guide to drugs and dry mouth. 2nd edn. Gerodontology 1997; 14: 33-47.
124. Ship JA, Fischer DJ. The relationship between dehydration and parotid salivary gland function in young and older healthy adults. J Gerontol A Biol Sci Med Sci 1997; 52A: M310-M319.
125. Wu AJ, Atkinson JC, Fox PC, Baum BJ, Ship JA. Cross-sectional and longitudinal analyses of stimulated parotid salivary constituents in healthy, different-aged subjects. J Gerontol 1993; 48: M219-M224.
126. Schein OD, Muñoz B, Tielsch JM, Bandeen-Roche K, West S. Prevalence of dry eye among the elderly. Am J Opthalmol 1997; 124: 723-728.
127. Drosos AA, Andonopoulos AP, Costopoulos JS, Papadimitrou CS, Moutsopoulos HM. Prevalence of primary Sjögren's syndrome in an elderly population. Br J Rheumatol 1988; 27: 123-127.
128. Strickland RW, Tesar JT, Berne BH, Hobbs BR, Lewis DM, Welton RC. The frequency of sicca syndrome in an elderly female population. J Rheumatol 1987; 14: 766-771.
129. Fox PI, Stern M, Michelson P. Update in Sjogren syndrome. Curr Opin Rheumatol 2000; 12: 391-398.
130. Garcia-Carrasco M, Cervera R, Rosas J et al. Primary Sjogren's syndrome in the elderly: clinical and immunological characteristics. Lupus 1999; 8: 20-23.
131. Haga HI, Jonsson R. The influence of age on disease manifestations and serological characteristics in primary Sjogren's syndrome. Scand J Rheumatol 1999; 28: 227-232.
132. Fox PC. Management of dry mouth. Dent Clin N Am 1997; 41: 863-875.
133. Corrigan AB, Robinson RG, Terenty TR, Dick-Smith JB, Walters D. Benign rheumatoid arthritis of the aged. Br Med J 1974; 1: 444-446.
134. Hazes JM, Dijkmans BA, Hoevers JM et al. DR4 prevalence related to the age at disease onset in female patients with rheumatoid arthritis. Ann Rheum Dis 1989; 48: 406-408.
135. van der Heijde DM, van Riel PL, van Leeuwen MA, van't Hof MA, van Rijswijk MH, van de Putte LB. Older versus younger onset rheumatoid arthritis: results at onset and after 2 years of a prospective followup study of early rheumatoid arthrifis. J Rheumatol 1991; 18: 1285-1289.
136. Salvarani C, Macchioni P, Mantovani W, Portioli I. Polymyalgia rheumatica and seronegative rheumatoid arthritis: some considerations based on a northern Italian population. J Rheumatol 1993; 20: 756-757.
137. van Schaardenburg D, Hazes JM, de Boer A, Zwinderman AH, Meijers KA, Breedveld FC. Outcome of rheumatoid arthritis in relation to age and rheumatoid factor at diagnosis. J Rheumatol 1993; 20: 45-52.
138. Terkeltaub R, Esdaile J, Decary F, Tannenbaum H. A clinical study of older age rheumatoid arthritis with comparison to a younger onset group. J Rheumatol 1983; 10: 418-424.
139. Healey LA, Sheets PK. The relation of polymyalgia rheumatica to rheumatoid arthritis. J Rheumatol 1988; 15: 750-752.
140. van Schaardenburg D, Lagaay AM, Otten HG, Breedveld FC. The relation between class-specific serum rheumatoid factors and age in the general population. Br J Rheumatol 1993; 32: 546-549.
141. Inoue K, Shichikawa K, Nishioka J, Hirota S. Older age onset rheumatoid arthritis with or without osteoarthritis. Ann Rheum Dis 1987; 46: 908-911.
142. Deal CL, Meenan RF, Goldenberg DL et al. The clinical features of elderly-onset rheumatoid arthritis. A comparison with younger-onset disease of similar duration. Arthritis Rheum 1985; 28: 987-994.
143. Yacizi Y and Paget SA. Onset of rheumatoid arthritis in the elderly. In: Rheumatic disease clinics of North America (Spanish edition). Panamericana: Madrid, pp 539-549.
144. Gary M. Kammer and Nilamadhab Mishra Lupus Eritematoso Sistémico en el anciano. In: Loeser RF Jr, O'Rourke KS (ed.). Rheumatic disease clinics of North America (Spanish edition). Panamericana: Madrid, pp 495-513.
145. Baker SB, Rovira JR, Campion EW, Mills JA. Late onset systemic lupus erythematosus. Am J Med 1979; 66: 727-732.
146. Ballou SP, Khan MA, Kushner I. Clinical features of systemic lupus erythematosus: differences related to race and age of onset. Arthritis Rheum 1982; 25: 55-60.
147. Catoggio LJ, Skinner RP, Smith G, Maddison PJ. Systemic lupus erythematosus in the elderly: clinical and serological characteristics. J Rheumatol 1984; 11: 175-181.
148. Font J, Pallares L, Cervera R et al. Systemic lupus erythematosus in the elderly: clinical and immunological characteristics. Ann Rheum Dis 1991; 50: 702-705.
149. Cervera R, Khamashta MA, Font J et al. Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. The European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore) 1993; 72: 113-124.
150. Koh ET, Boey ML. Late onset lupus: a clinical and immunological study in a predominantly Chinese population. J Rheumatol 1994; 21: 1463-1467.
151. Ho CT, Mok CC, Lau CS, Wong RW. Late onset systemic lupus erythematosus in southern Chinese. Ann Rheum Dis 1998; 57: 437-440.
152. Urowitz MB, Stevens MB, Shulman LE. The influence of age on clinical pattern of systemic lupus erythematosus. Arthritis Rheum 1967; 10: 319-320.
153. Hochberg MC, Boyd RE, Ahearn JM et al. Systemic lupus erythematosus: a review of clinico-laboratory features and immunogenetic markers in 150 patients with emphasis on demographic subsets. Medicine (Baltimore) 1985; 64: 285-295.
154. Maddison PJ. Systemic lupus erythematosus in the elderly. J Rheumatol 1987; 14(Suppl 13): 182-187.
155. Domenech I, Aydintug O, Cervera R, Khamashta M, Jedryka-Goral A, Vianna JL, Hughes GR. Systemic lupus erythematosus in 50 year olds. Postgrad Med J 1992; 68: 440-444.
156. Costallat LT, Coimbra AM. Systemic lupus erythematosus: clinical and laboratory aspects related to age at disease onset. Clin Exp Rheumatol 1994; 12: 603-607.
157. Hooper B, Whittingham S, Mathews JD, Mackay IR, Cumow DH. Autoimmunity in a rural community. Clin Exp Immunol 1972; 12: 79-87.
158. Juby AG, Davis P, McElhaney JE, Gravenstein S. Prevalence of selected autoantibodies in different elderly subpopulations. Br J Rheumatol 1994; 33: 1121-1124.
159. Svec KH, Veit BC. Age-related antinuclear factors: immunologic characteristics and associated clinical aspects. Arthritis Rheum 1967; 10: 509-516.
160. Hahn BH, Tsao BP. Antibodies to DNA In: Wallace DJ, Hahn BH (eds). Dubois' Lupus Erythematosus. Wilkins: Baltimore, 1997, pp 407-422.
161. Sanchez-Guerrero J, Lew RA, Fossel AH, Schur PH. Utility of anti-Sm, anti-RNP, anti-Ro/SS-A, and anti-La/SS-B (extractable nuclear antigens) detected by enzyme-linked immunosorbent assay for the diagnosis of systemic lupus erythematosus. Arthritis Rheum 1996; 39: 1055-1061.
162. Klippel JH. Immunosupressive therapy: antimalarians, cytotoxic agents and azathioprine. In: Lahita RG (ed.). Systemic lupus erythematosus, 2nd edn. Churchill Livingstone: New York, 1992, pp 907-932.
163. Rynes RI. Ophthalmologic safety of long-term hydroxychloroquine sulfate treatment. Am J Med 1983; 75: 35-39.
164. Wallace DJ. The use of quinacrine (Atabrine) in rheumatic diseases: a reexamination. Semin Arthritis Rheum 1989; 18: 282-296.
165. Richards AJ. Hydroxychloroquine myopathy. J Rheumatol 1998; 25: 1642-1643.
166. Gottlieb NL, Penneys NS. Spontaneous skin tearing during systemic corticosteroid treatment. J Am Med Assoc 1980; 243: 1260-1261.
167. Ling MH, Perry PJ, Tsuang MT. Side effects of corticosteroid therapy. Psychiatric aspects. Arch Gen Psychiat 1981; 38: 471-477.
168. Saville PD, Kharmosh O. Osteoporosis of rheumatoid arthritis: influence of age, sex and corticosteroids. Arthritis Rheum 1967; 10: 423-430.
169. Rosove MH, Brewer PM. Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann Intern Med 1992; 117: 303-308.
170. Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GR. The management of thrombosis in the antiphospholipid-antibody syndrome. New Engl J Med 1995; 332: 993-997.
171. Font J, Lopez-Soto A, Cervera R et al. The 'primary' antiphospholipid syndrome: antiphospholipid antibody pattern and clinical features of a series of 23 patients. Autoimmunity 1991; 9: 69-75.
172. Vianna JL, Khamashta MA, Ordi-Ros J et al. Comparison of the primary and secondary antiphospholipid syndrome: a European Multicenter Study of 114 patients. Am J Med 1994; 96: 3-9.
173. Cabral AR, Cabiedes J, Alarcon-Segovia D. Antibodies to phospholipid-free beta 2-glycoprotein-I in patients with primary antiphospholipid syndrome. J Rheumatol 1995; 22: 1894-1898.
174. Krnic-Barrie S, O'Connor CR, Looney SW, Pierangeli SS, Harris EN. A retrospective review of 61 patients with antiphospholipid syndrome. Analysis of factors influencing recurrent thrombosis. Arch Intern Med 1997; 157: 2101-2108.
175. Asherson RA, Cervera R, Piette JC et al. Catastrophic antiphospholipid syndrome. Clinical and laboratory features of 50 patients. Medicine (Baltimore) 1998; 77: 195-207.
176. Andre E, Siguret V, Alhenc-Gelas M, Saint-Jean O, Gaussem P. Venous thrombosis in older people: prevalence of the factor V gene mutation Q506. J Am Geriatr Soc 1998; 46: 1545-1549.
177. The Antiphospholipid Antibodies in Stroke Study (APASS) Group. Anticardiolipin antibodies are an independent risk factor for first ischemic stroke. Neurology 1993; 43: 2069-2073.
178. Piette JC, Cacoub P, Wechsler B. Renal manifestations of the antiphospholipid syndrome. Semin Arthritis Rheum 1994; 23: 357-366.
179. Quintarelli C, Ferro D, Valesini G, Basili S, Tassone G, Violi F. Prevalence of lupus anticoagulant in patients with cirrhosis: relationship with beta-2-glycoprotein I plasma levels. J Hepatol 1994; 21: 1086-1091.
180. Chakravarty K, Pountain G, Merry P, Byron M, Hazleman B, Scott DG. A longitudinal study of anticardiolipin antibody in polymyalgia rheumatica and giant cell arteritis. J Rheumatol 1995; 22: 1694-1697.
181. Zuckerman E, Toubi E, Golan TD, Rosenvald-Zuckerman T, Sabo E, Shmuel Z, Yeshurun D. Increased thromboembolic incidence in anticardiolipin-positive patients with malignancy. Br J Cancer 1995; 72: 447-451.
182. Palareti G, Leali N, Coccheri S et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 1996; 348: 423-428.
183. Schved JF, Dupuy-Fons C, Biron C, Quere I, Janbon C. A prospective epidemiological study on the occurrence of antiphospholipid antibody: the Montpellier Antiphospholipid (MAP) Study. Haemostasis 1994; 24: 175-182.
184. Guerin J, Feighery C, Sim RB, Jackson J. Antibodies to beta-2glycoprotein I - a specific marker for the antiphospholipid syndrome. Clin Exp Immunol 1997; 109: 304-309.
185. Piette JC, Cacoub P. Antiphospholipid syndrome in the elderly: caution. Circulation 1998; 97: 2195-2196.
186. Puisieux F, Woesteland H, Hachulla E, Hatron PY, Dewailly P, Devulder B. Clinical symptomatology and prognosis of periarteritis nodosa in the elderly. Retrospective study of 25 periarteritis nodosa cases in young adults and 22 cases in aged patients. Rev Med Intern 1997; 18: 195-200.
187. Guillevin L, Lhote F, Gayraud M et al. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. Medicine (Baltimore) 1996; 75: 17-28.
188. Mouthon L, Toumelin PL, Andre MH, Gayraud M, Casassus P, Guillevin L. Polyarteritis nodosa and Churg-Strauss angiitis. Medicine (Baltimore) 2002; 81: 27-40.
189. Vassallo M, Shepherd RJ, Iqbal P, Feehally I. Age-related variations in presentation and outcome in Wegener's granulomatosis. J R Coll Phys Lond 1997; 31: 396-400.
190. Kyndt X, Launay D, Hebbar M et al. Influence of age on the clinical and biological characteristics of systemic scleroderma. Rev Med Intern 1999; 20: 1088-1092.